Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Deferred Revenue: 2021-2025

Historic Current Deferred Revenue for Autolus Therapeutics (AUTL) over the last 4 years, with Sep 2025 value amounting to $7.6 million.

  • Autolus Therapeutics' Current Deferred Revenue fell 96.26% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 96.26%. This contributed to the annual value of $35.0 million for FY2022, which is 25.53% down from last year.
  • Per Autolus Therapeutics' latest filing, its Current Deferred Revenue stood at $7.6 million for Q3 2025, which was up 262.48% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Current Deferred Revenue registered a high of $219.4 million during Q1 2025, and its lowest value of $2.1 million during Q2 2025.
  • Its 3-year average for Current Deferred Revenue is $136.0 million, with a median of $140.8 million in 2023.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 168.70% in 2023, then crashed by 98.93% in 2025.
  • Over the past 5 years, Autolus Therapeutics' Current Deferred Revenue (Quarterly) stood at $47.0 million in 2021, then declined by 25.53% to $35.0 million in 2022, then surged by 168.70% to $140.8 million in 2023, then surged by 44.46% to $203.4 million in 2024, then slumped by 96.26% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q3 2025, $2.1 million for Q2 2025, and $219.4 million during Q1 2025.